BactiQuant (BACTIQ) Q4 2025 TU earnings summary

Executive summary

• Revenue in 2025 reached DKK 8.3 million, representing a 16% increase year-over-year, with the strongest growth in the Pharma segment and solid advances in Aquaculture and Water Utility.

• Recurring sales, particularly consumables for BactiQuant Online, more than doubled from 2024 to 2025 and are expected to double again in 2026 as more online samplers are deployed.

• Hardware sales underperformed expectations due to longer customer decision processes, while recurring revenue showed moderate growth.

Financial highlights

• Total revenue for 2025 was DKK 8.3 million, up 16% from the previous year.

• Liquidity at year-end 2025 stood at DKK 17.9 million, bolstered by a capital raise in November 2025 that netted DKK 15.8 million.

Outlook and guidance

• Revenue for 2026 is projected between DKK 10 and 13 million.

• EBITDA for 2026 is expected to be in the range of DKK -7 to -10 million.

• Sufficient liquidity is anticipated through the end of 2027 based on current strategic and financial plans.